Processa Pharmaceuticals Terminates Licensing Agreement With Ocuphire Pharma - SEC Filing
July 1 (Reuters) - Processa Pharmaceuticals Inc PCSA.O:
PROCESSA PHARMACEUTICALS INC - TERMINATES LICENSING AGREEMENT WITH OCUPHIRE PHARMA - SEC FILING
PROCESSA PHARMACEUTICALS INC - ANNOUNCES STRATEGIC PORTFOLIO REVIEW AND PIPELINE REALIGNMENT
PROCESSA PHARMACEUTICALS INC - GRANTS INTACT THERAPEUTICS EXCLUSIVE OPTION TO LICENSE PCS12852
Source text: [ID:n0001641172-25-017288]
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
AMD Q1 Earnings: Data Center Revenue Surges 57% Driving Results Above Estimates, Shares Rise Over 16% After Hours

Dell Stock Analysis: Is It Still Undervalued and the Best AI Infrastructure Play by 2026?

Vanguard ETF Could Beat the S&P 500 Again in 2026 —— Why Investors Are Paying Attention

Micron Stock Forecast: Can the AI Memory Super-Cycle Drive MU to $3,000 by 2030?

Meta Stock Price Forecast 2026-2030: Can META Hit $1,000?

Tradingkey







